الفهرس 
Non-Hodgkin’s LymphomaOnly 14 pages are availabe for public view
 |  | from | 137 |  |  |
| | | from | 137 | | |
Abstract
The non-Hodgkin’s lymphomas (NHLs) are a collection of lymphoid malignancies with a diverse pathology and natural history. NHLs despite being initially chemosensitive, they become eventually refractory. Multidrug resistance (MDR) is the protection of a tumor cell population against numerous drugs differing in chemical structure and mechanisms of influence on the cells. It is still unclear whether overexpression of MDR-1 gene plays a role in the chemotherapy resistance in lymphoma. This study was designed to assess P-gp expression in lymphoma patients and to observe the impact effect of P-gp level upon chemotherapy response. In this study we assessed the expression of MDR-1 in 29 patients with NHL using monoclonal antibodies by flowcytometric method. We found that: 1- There is non significant difference in the frequency of P-gp expression regarding the age and the gender. 2- There is a significant increase in LDH and decrease in HB level in the relapsed NHL group when compared with both de novo and the control group. 3- There is increased expression of P-gp in non-Hodgkin’s lymphoma more than the control group. 4- P-gp expression is higher in relapsed NHL than NHL at diagnosis (de novo). 5- There is non significant difference in the frequency of P-gp expression regarding different pathological types. Meanwhile, there was significant increase in the level of MDR-1 expression in the high grade NHL patients when compared with both low and intermediate grades. 6- There is non significant difference in frequency of P-gp expression regarding different stages. Meanwhile, there was significant increase in MDR-1 expression in stage III and IV compared with stage II with non significant difference in MDR-1 expression between stage III and IV. 7- Patients with positive MDR-1 expression have higher incidence of resistance to chemotherapy and failure to achieve complete remission, than patients with negative MDR-1.